A machine learning-based prediction model for treatment efficacy in smear and/or chest X-ray positive tuberculosis patients

Read full text Summarise with VIRAT
Authors: Xiaohua Cui, Wei Fu, Xuan Wu, Zhe Peng, Wentao Wu
Cited by: 0
References: 26

Summary

No summary yet. VIRAT can read this paper and write a plain-language summary of its aim, methods, key findings and limitations.

Summarise with VIRAT Free to try with your Science Catalogs account.

Abstract

OBJECTIVE: To develop a machine learning (ML)-based prediction model for tuberculosis (TB) treatment failure, and evaluate the predictive performance and clinical utility. METHODS: Patients were randomly allocated to a training set and a validation set in a 7:3 ratio. Data collected included demographic characteristics, clinical features, and laboratory parameters. Univariate analysis and binary logistic regression were applied to the training set to identify factors associated with treatment outcome. Based on common predictive modeling standards, an AUC > 0.8 was considered good, and > 0.9 was considered excellent. Three prediction models—Random Forest (RF), Support Vector Machine (SVM), and K-Nearest Neighbors (KNN)—were constructed. Model performance was evaluated based on accuracy, precision, recall, F1-score, and the area under the receiver operating characteristic curve (AUC). RESULTS: Among 541 enrolled patients, 133 (24.58%) experienced treatment failure (92 [24.27%] in the training set and 41 [25.31%] in the validation set).Cavitation, diabetes comorbidity, radiographic disease extent, TB type (pulmonary vs. extrapulmonary), lymphocyte percentage (LYMPH%), and serum albumin (ALB) level were identified as significant predictors of treatment outcome (P < 0.05). The RF, SVM, and KNN models achieved AUC values of 0.783, 0.707, and 0.668, respectively. CONCLUSION: The ML-based prediction model shows fair to good predictive performance (AUC up to 0.783), suggesting potential clinical utility with further validation. This model may assist in early risk stratification and support individualized treatment planning for tuberculosis patients. CLINICAL TRIAL NUMBER: Not applicable.

Fields of Study & Subjects

Tuberculosis Research and Epidemiology Artificial Intelligence in Healthcare Infectious Diseases and Tuberculosis

Publication details

Journal / source
BMC Infectious Diseases
Volume
26
Issue
1
Publication date
27 March 2026
Language
EN